NASDAQ: CNTX - Context Therapeutics Inc.

半年間の収益性: +50.38%
セクタ: Healthcare

プロモーションスケジュール Context Therapeutics Inc.


会社について

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.


EBITDA -0.0054
Число акций ао 0.01597 млрд
P/BV 0.9592
EV/EBITDA -4.02
Цена ао 1.27
ISIN US21077P1084
Сайт https://www.contexttherapeutics.com
Валюта usd
IPO date 2021-10-20
Sector Health Care
Industry Pharmaceuticals
Валюта отчета usd
1日あたりの価格変動: -0.5051% (1.98)
週ごとの価格変動: +5.91% (1.86)
月ごとの料金変更: -13.6% (2.28)
3ヶ月間の価格変動: +7.07% (1.84)
半年間の価格変動: +50.38% (1.31)
年間の価格変動: +45.93% (1.35)
年初からの価格変動: +95.05% (1.01)

過小評価

名前 意味 学年
P/S 0 0
P/BV 1.55 8
P/E 0 0
EV/EBITDA -0.1593 0
合計: 3.5

効率

名前 意味 学年
ROA, % -149.19 0
ROE, % -201.87 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.0022 10
合計: 9.8

成長の衝動

名前 意味 学年
収益性 Revenue, % 0 0
収益性 Ebitda, % 364.08 10
収益性 EPS, % 104.74 10
合計: 8



スーパーバイザー 役職 支払い 生年
Mr. Martin A. Lehr Co-Founder, President, CEO & Director 674.08k 1984 (40 年)
Ms. Jennifer Minai-Azary CFO & Treasurer 504.14k 1978 (46 年)
Mr. Alex C. Levit Esq. Chief Legal Officer & Corporate Secretary 483.83k 1979 (45 年)
Mr. Christopher Beck M.B.A. Senior Vice President of Operations N/A
Dr. Claudio Dansky Ullmann M.D. Chief Medical Officer

住所: United States, Philadelphia. PA, 2001 Market Street - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.contexttherapeutics.com